Compare VRA & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | ONCY |
|---|---|---|
| Founded | 1982 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Apparel | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.4M | 98.7M |
| IPO Year | 2010 | 2002 |
| Metric | VRA | ONCY |
|---|---|---|
| Price | $3.37 | $0.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 155.9K | ★ 1.1M |
| Earning Date | 06-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $416,097,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.50 | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $0.33 |
| 52 Week High | $4.39 | $1.51 |
| Indicator | VRA | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 38.73 |
| Support Level | $2.35 | $0.78 |
| Resistance Level | $3.80 | $1.18 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 20.09 | 20.44 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.